NCT06468670View on ClinicalTrials.gov

Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

June 17, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2027

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG

sintilimab，programmed death 1 monoclonal antibody

"short-course radiotherapy~+sintilimab (200mg, iv, D1, Q3W)"

All Listed Sponsors

lead

Fujian Cancer Hospital

OTHER_GOV